Expanded Access to Telisotuzumab Vedotin

NCT04830202 | Unknown

• 1 other identifier: C20-503
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Keywords

Non-Small Cell Lung Cancer (NSCLC); Telisotuzumab vedotin; ABBV-399; Expanded Access; Pre-approval Access; Compassionate Use; Special Access Program; Named Patient Basis; Special Access Scheme

Interventions

Telisotuzumab vedotin DRUG

Intravenous Infusion

Also known as: ABBV-399

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• There are other suitable treatment options.
• The participant qualifies for ongoing clinical trials.

Sponsors & Collaborators

• AbbVie: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

telisotuzumab vedotin

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• ABBVIE INC.

  AbbVie

  STUDY DIRECTOR

Central Study Contacts

ABBVIE CALL CENTER

CONTACT

844-663-3742; abbvieclinicaltrials@abbvie.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 31, 2021
• First Posted: April 5, 2021
• Last Updated: February 6, 2026

Record last verified: 2025-09